Syros Pharmaceuticals (SYRS) to Release Quarterly Earnings on Wednesday

Syros Pharmaceuticals (NASDAQ:SYRS) is projected to release its earnings data before the market opens on Wednesday, March 26th. Analysts expect Syros Pharmaceuticals to post earnings of ($0.70) per share for the quarter.

Syros Pharmaceuticals Price Performance

Syros Pharmaceuticals stock opened at $0.06 on Monday. The firm has a market capitalization of $1.65 million, a P/E ratio of -0.02 and a beta of 1.31. Syros Pharmaceuticals has a one year low of $0.06 and a one year high of $6.93. The business has a fifty day moving average price of $0.16 and a 200-day moving average price of $0.85.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Syros Pharmaceuticals in a research report on Friday. They set a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $3.33.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.